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Abstract
 
The development of a permissive small animal model for the study of human immunodeficiency
virus type (HIV)-1 pathogenesis and the testing of antiviral strategies has been hampered by the
inability of HIV-1 to infect primary rodent cells productively. In this study, we explored trans-
genic rats expressing the HIV-1 receptor complex as a susceptible host. Rats transgenic for hu-
man CD4 (hCD4) and the human chemokine receptor CCR5 (hCCR5) were generated that
express the transgenes in CD4
 

 
 T lymphocytes, macrophages, and microglia. In ex vivo cul-
tures, CD4
 

 
 T lymphocytes, macrophages, and microglia from hCD4/hCCR5 transgenic rats
were highly susceptible to infection by HIV-1 R5 viruses leading to expression of abundant lev-
els of early HIV-1 gene products comparable to those found in human reference cultures. Pri-
mary rat macrophages and microglia, but not lymphocytes, from double-transgenic rats could be
productively infected by various recombinant and primary R5 strains of HIV-1. Moreover, after
systemic challenge with HIV-1, lymphatic organs from hCD4/hCCR5 transgenic rats con-
tained episomal 2–long terminal repeat (LTR) circles, integrated provirus, and early viral gene
products, demonstrating susceptibility to HIV-1 in vivo. Transgenic rats also displayed a low-
level plasma viremia early in infection. Thus, transgenic rats expressing the appropriate human
receptor complex are promising candidates for a small animal model of HIV-1 infection.
Key words: HIV-1 • transgenic rats • CD4 • CCR5 • macrophages
 
Introduction
 
New small animal models of HIV-1 disease are needed to
complement present models in the study of viral pathogene-
sis, the screening of new drugs, and the testing of vaccine
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strategies. Limitations of existing animal models include the
availability and high cost of nonhuman primates, the ab-
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sence or delayed progression to an acquired immunodefi-
ciency syndrome in some of these models, or permissivity
only for related retroviruses (1–3). Current xenotransplant
models are informative about select aspects of HIV-1 patho-
genesis (4, 5), but present neither a complete range of in-
fected tissues nor the context of an intact immune response.
HIV-1 replication is subject to a variety of potent spe-
cies-specific restrictions in cells from many nonprimate
species (6–10). Over the past years, a number of advances
have been made elucidating the molecular bases of such
blocks to HIV-1 replication, and these discoveries have re-
charged efforts to develop transgenic small animal models
permissive for HIV-1 infection in the context of an intact
immune system. Regarding cellular entry, coexpression of
hCD4 and a human chemokine receptor were shown to
overcome the entry block in primary T lymphocytes from
mice transgenic for either hCD4 and hCCR5 (11) or
hCD4 and human CXCR4 (hCXCR4) (12), but these
mouse cells exhibited very little or no productive infection.
Another restriction to HIV-1 replication in mouse cells is
the limited efficiency of the viral regulator, Tat, in activat-
ing transcription and transcript elongation from the long
terminal repeat (LTR)
 
*
 
 of HIV-1, which are normally cru-
cial steps for vigorous viral replication. Recently, a novel
Tat-interacting protein, human cyclin T1 (hCycT1) was
identified (13). hCycT1 was shown to be crucial to the
transcriptional block in mouse cells since expression of
hCycT1 drastically enhanced transcriptional activity in
mouse NIH 3T3 fibroblasts (13–19) and in primary lym-
phocytes from transgenic mice (unpublished data). How-
ever, 3T3 cells expressing hCD4, hCCR5, and hCycT1
were still unable to support the full HIV-1 replication cycle
(16, 17). In this context, a viral assembly block in 3T3 cells
was reported (16) that could pose a species-specific, post-
transcriptional barrier to HIV-1 replication. Interestingly,
this HIV-1 assembly block could be partially comple-
mented by mouse–human heterokaryon fusions (17, 18)
suggesting that these mouse fibroblasts lack a specific posi-
tive factor required for efficient virus assembly and release.
An alternate approach to small animal model develop-
ment is the identification of other species that are less re-
stricted for the HIV-1 replication cycle but nonetheless
susceptible to transgenic manipulation. In certain rat cell
lines, cellular entry constitutes the only absolute block to
HIV-1 replication and this restriction can be overcome by
coexpression of hCD4 and hCCR5 (19). We and others
have identified quantitative and qualitative limitations in
various aspects of the HIV-1 replication cycle in rat cell
lines (17–19) that appear to be largely cell type–specific,
rather than species specific. Importantly, in the context of
infections with HIV-1 pseudotypes containing the vesicular
stomatitis virus G protein (VSV-G), primary nontransgenic
rat cells from the monocyte/macrophage lineage supported
all postentry steps in the viral life cycle and secreted sub-
stantial levels of infectious virions (19). Furthermore, un-
like native mouse and hamster cells, most rat-derived cells
supported a robust HIV-1 LTR activity (17–19). This con-
clusion is also confirmed by a recent report showing that
HIV-1 transgenic rats carrying an HIV-1 provirus with
functional deletions in 
 
gag
 
 and 
 
pol,
 
 expressed gp120, Tat,
and Nef proteins in spleen tissue (20). Although overex-
pression of hCycT1 thus appears to be nonessential for effi-
cient LTR transactivation in rat cells, our data indicated
that the activity of CycT1 may still be a quantitatively lim-
iting factor in this species context (19).
In addition, rats offer several practical advantages for
their use as an animal model for HIV-1 infection, including
their short gestation time, size, and well-characterized im-
mune system and central nervous system (CNS). In partic-
ular, rats have long been considered a valuable model for
studying the development and function of the CNS and
they are used extensively to study the molecular mecha-
nisms underlying HIV-related CNS pathology (21–23).
Rats have also been used frequently as a model organism
for basic pharmacological studies, including pharmacoki-
netic and pharmacodynamic studies on current anti-HIV
drugs (24–26). Furthermore, rat transgenesis can be per-
formed with relative ease, thereby enabling the selective
expression of human genes that may be essential for full re-
alization of the HIV-1 replication cycle in this species.
In humans, T lymphocytes as well as cells from the
monocyte/macrophage lineage, including microglia, are
considered to be the most important sites of HIV-1 repli-
cation in vivo (27, 28). To mimic the pattern of suscepti-
ble tissues and viral pathogenesis in a transgenic rat model,
these cell types must express the human transgenes essen-
tial for complementation of the HIV-1 replication cycle.
Although HIV-1 entry can be mediated by hCD4 acting
with one of several members of the human chemokine re-
ceptor superfamily or related coreceptors (29), hCCR5
appears to be the critical coreceptor required for transmis-
sion and establishment of an infection in humans. Key
pieces of evidence in support of this are the almost exclu-
sive presence of CCR5-dependent (R5) viruses in early
HIV-1 disease (30) and the high degree of resistance to
HIV-1 infection observed in exposed individuals homozy-
gous for a 32-basepair deletion in their CCR5 gene (
 

 
32
 
CCR5
 
), which prevents the presentation of hCCR5 at the
cell surface (31).
Here we report the generation of transgenic rats that co-
express hCD4 and hCCR5 on CD4
 

 
 T lymphocytes,
macrophages, and microglia. Coexpression of these human
transgenes rendered primary rat cells permissive for infec-
tion by R5 viruses. In ex vivo cultures, cells of the mono-
cyte/macrophage lineage from these animals could be pro-
ductively infected by various R5 viruses at levels one to
two orders of magnitude higher than those described for
comparable transgenic mouse models (11, 12). In vivo,
hCD4/hCCR5 transgenic rats challenged systemically
 
*
 
Abbreviations used in this paper:
 
 AZT, zidovudine; CNS, central nervous
system; CycT1, cyclin T1; Env, envelope; ID, rodent identifier; LTR,
long terminal repeat; MIP, macrophage inflammatory protein; MOI,
multiplicity of infection; RANTES, regulated upon activation, normal T
cell expressed and secreted; RTV, Ritonavir; SIV, simian immunodefi-
ciency virus; VSV-G, vesicular stomatitis virus G protein.
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with HIV-1 showed clear evidence of successful infection
demonstrated by detection of episomal and integrated
HIV-1 cDNA, and early gene expression in cells from
spleen, thymus, and blood. Low-level plasma viremia was
detectable in transgenic rats up to 7 wk after inoculation.
These important steps provide a strong foundation for
studies that will address the extent of HIV-1 replication,
pathogenesis, and immune responses to HIV-1 in trans-
genic rats in vivo and elucidate their potential for testing of
antiviral strategies.
 
Materials and Methods
 
Construction of Transgenic Rats.
 
The transgenic vector for
hCD4 has been described previously (32). The vector encoding
hCCR5 was prepared to ensure expression in Th cells and in cells
from the monocyte/macrophage lineage. For this purpose, an
8.4-kb BstBI-BamHI fragment from intron 1 of the human CD4
gene, shown to contain a monocyte-specific enhancer as well as
the CD4 silencer (unpublished data), was inserted as a replace-
ment for the ClaI–HindIII fragment in the middle of intron 1 in
the murine construct “b,” described previously (33). A 1.15-kb
hCCR5 cDNA was inserted into the SalI site in exon 2, replacing
the hCD2 cDNA in construct “b,” thus yielding the plasmid
pM
 

 
E4A.CCR5 (Fig. 1 B). For preparation of transgenic rats,
the plasmid vector sequences were excised by digestion with
NotI. Rat founders for individual transgenic constructs were gen-
erated (Xenogen) by microinjection of the vector DNA into
male pronuclei of fertilized oocytes from outbred Sprague-Daw-
ley rats. Founders for the hCD4 transgene were identified by
Southern blot analysis of EcoRV-digested tail DNA samples us-
ing a HindIII–BamHI fragment from pCD4neo (19) as a probe.
Founders for hCCR5 were identified by PCR analysis from tail
DNA samples using an internal primer set for hCCR5 cDNA
(5
 

 
 primer: TCACTATGCTGCCGCCC. 3
 

 
 primer: AAACC-
AAAGTCCCACTGGGCG). Integration-positive founders were
mated with nontransgenic Sprague-Dawley rats and F1 progeny
were screened by flow cytometry for expression of human pro-
teins in peripheral blood samples.
 
Antibodies and Flow Cytometry.
 
FACS
 
®
 
 analyses were per-
formed as described previously (34), using FITC-, PE-, or APC-
conjugated mAbs (BD PharMingen): anti-hCD4 (mAb Leu-3a);
anti-hCCR5 (mAb 2D7); anti–rat (r)CD3 (mAb G4.18); anti-
rCD4 (mAb OX-35); anti-rCD8a (mAb OX-8); anti–rat
macrophage subset marker (ED2-like antigen, mAb HIS36);
anti-rCD11b (mAb WT.5); anti-rCD11b/c (mAb OX-42); and
anti-rCD45RA (mAb OX-33).
 
Immunohistochemistry.
 
A standard three-step immunoperoxi-
dase procedure using the Dako LSAB (R) 2 kit (Dako) was per-
formed on formalin-fixed, paraffin-embedded tissues from PBS-
perfused rats in principle as described previously (35). Tissues
were sectioned onto silanized slides, allowed to dry, deparaf-
finized, and hydrated through graded ethanols. The tissues were
pretreated with 3% H
 
2
 
O
 
2
 
 for 10 min to block endogenous per-
oxidases, heat-treated in citrate buffer, pH 6.0, for 10 min to re-
trieve antigens and finally buffered in PBS/casein. The slides
were incubated with primary antibodies (anti-hCD4 mAb 1F6
[1:10]; Novacastra, or anti-hCCR5 mAb 3A9 [1:10]; BD
PharMingen) for 2 h at room temperature, washed, and then
stained after the kit protocol with 30-min incubations and final
DAB reaction.
 
Primary Cells and Cultivation.
 
Ex vivo cultures of primary rat
lymphocytes, macrophages, or microglia, and cultures of PBMCs
or human monocyte–derived macrophages were prepared and
propagated as described previously (19).
 
Chemotaxis Assay.
 
The migration of rCD4
 

 
-enriched pri-
mary rat splenocytes was determined by using a modification of
the method described by Arai et al. (36) with Transwell
 
®
 
 plates
(pore size: 3 
 

 
m; diameter: 6.5 mm, Costar
 
®
 
; Corning, Inc.) and
recombinant chemokines (R&D Systems).
 
Preparation of Viral Stocks.
 
Molecular clones of pYU-2, pJR-
CSF, and pNL4–3 were obtained from Beatrice Hahn (Univer-
sity of Alabama at Birmingham, Birmingham, AL), Irvin Chen
(UCLA School of Medicine, Los Angeles, CA), and Malcom
Martin (National Institutes of Health, Bethesda, MD), respec-
tively, via the National Institutes of Health (NIH) AIDS Re-
search and Reference Reagent Program. pYU-2b, a YU-2/
HXB2 recombinant (37), was a gift from Warner Greene (Glad-
stone Institute of Virology and Immunology, San Francisco,
CA). The molecular clone p49–5 (38) was a gift from Bruce
Chesebro (Rocky Mountain Laboratories, Hami Hou, MT).
pR7/3-YU-2-EGFP (39)
 
,
 
 which carries an EGFP gene within
the 
 
nef
 
 locus driven by the 5
 

 
 LTR, was a gift from Mark Mues-
ing (Aaron Diamond AIDS Research Center, New York, NY).
Infectious virus stocks were prepared by transfecting 293T cells
with proviral DNA as described previously (34). Viral stocks of
JR-FL and Ada-M were obtained from Irvin Chen and Howard
Gendelman (University of Nebraska Medical Center, Omaha,
NE), respectively, via the NIH AIDS Research and Reference
Reagent Program. The primary isolates C1 (40) and O3 (41)
were gifts from James Mullins (University of Washington, Seat-
tle, WA) and Ruth Connor (Aaron Diamond AIDS Research
Center), respectively. Viral stocks were expanded by infection of
heterologous human PBMCs. Infectious Ba-L stocks, which had
been expanded on human monocyte-derived macrophages,
were a gift from Teri Liegler (Gladstone Institute of Virology
and Immunology).
For in vivo infections, YU-2 and R7/3-YU-2-EGFP stocks
were concentrated using Centricon
 
®
 
 Plus-80 columns (Millipore)
following the manufacturer’s protocol. The infectivity of viral
stocks was determined by terminal dilution in quadruplicate on
heterologous phytohemagglutinin-activated PBMCs. The titer of
R7/3-YU-2-EGFP stocks was determined on HeLa hCD4/
hCCR5 cells. The p24 CA concentration was assessed by ELISA
(NEN Life Sciences). The molecular clone pNL-4–3 Luc E
 
–
 
R
 
–
 
(42), a replication-incompetent NL4–3 provirus (along with mu-
tations in 
 
env
 
, 
 
nef
 
, and 
 
vpr
 
), carrying a luciferase gene within the
 
nef
 
 locus driven by the 5
 

 
 LTR, was a gift of Nathaniel Landau
(Salk Institute for Biological Studies, La Jolla, CA) via the NIH
AIDS Research and Reference Reagent Program. pVSV-G, the
mammalian expression vector for VSV-G protein (43), was a gift
from Jane Burns (University of California, San Diego, CA). The
preparation of NL4–3 Luc E
 

 
R
 

 
 pseudotype viruses with autolo-
gous or heterologous envelopes (Env) has been described previ-
ously (44).
 
Viral Infections.
 
HIV-1 infections of ex vivo cultures were
performed in 24-well (lymphocytes, macrophages) or 96-well
plates (microglia, macrophages) with the indicated multiplicity of
infection (MOI) or p24 CA concentrations. In infection studies
on transgenic rat macrophages shown in Figs. 5 and 6, the fol-
lowing reagents were used: anti-hCCR5 mAb 2D7 (BD Phar-
Mingen) at 50 
 

 
g/ml; zidovudine (AZT) (3
 

 
-azido-
3
 

 
deoxythymidine; Sigma-Aldrich) at 100 
 

 
M; Ritonavir (RTV)
(Abbott Laboratories, Abbott Park, IL) at 1 
 

 
M; LPS (
 
Escherichia
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coli
 
 serotype 0128:B12; Sigma-Aldrich) at 100 ng/ml; or a forma-
lin-fixed 
 
Staphylococcus aureus
 
 crude cell suspension (Sigma-
Aldrich) at 0.01%. In vivo infections were performed by trained
personnel in accordance with the guidelines and standards for hu-
mane animal experimentation set by the UCSF Committee on
Research under an approved protocol. All rats were housed un-
der SPF conditions with food and water ad libitum. For intrave-
nous and intraperitoneal injections, rats were deeply anesthetized
using isoflurane, and the tail vein or peritoneal cavity was cannu-
lated with a 24G Abbocath
 
®
 
-T catheter (Abbott Laboratories)
and YU-2 or R7/3-YU-2-GFP stocks were slowly infused (see
specific Figure legends for viral titers). On the indicated days after
inoculation, rats were killed with CO
 
2
 
 and bilateral thoracotomy
and organs were removed aseptically. Coded splenocyte, thy-
mocyte, and PBMC samples were analyzed for the presence of
HIV-1 cDNA products by PCR as described below. GFP-posi-
tive cells were detected by FACS
 
®
 
 analyses. Serial blood samples
were drawn from the jugular vein. HIV-1 vRNA assays of coded
rat EDTA-treated plasma samples were performed by the Glad-
stone Core Virology Laboratory using the AMPLICOR HIV-1
MONITOR
 
®
 
 test version 1.5 (gift from Roche Diagnostics).
 
Quantification of 2-LTR Circle Junctions.
 
2-LTR circle junc-
tions were amplified by PCR from extracts of extrachromosomal
DNA and quantified by Southern blotting as described previously
(45).
 
Detection of Integrated Proviral DNA.
 
A nested PCR strategy
for the specific amplification of HIV-1 proviral DNA that is inte-
grated into the rat genome was developed based on a previously
reported method to evaluate HIV-1 integration close to human
genomic 
 
Alu
 
 elements (46). We used a rodent identifier (ID)
family consensus sequence that is highly abundant in the rat ge-
nome (47), to design the oligonucleotide primer BC1-A (5
 

 
-
GGATTTAGCTCAGTGGTAGA-3
 

 
). Genomic DNA was ex-
tracted from formaldehyde-fixed cells using the DNAeasy
 
®
 
 tissue
kit (QIAGEN). During the first PCR reaction, cellular DNA was
amplified with the HIV-1 LTR primer A (5
 

 
-AGGCAAGCTT-
TATTGAGGCTTAAGC-3
 

 
; reference 46) and primer BC1-A.
 
Taq
 
 DNA polymerase (0.75 U/25 
 

 
l reaction; Stratagene), 200
 

 
M of each dNTP and 500 nM of each primer were used. The
reaction was run with the following program: (a) 3 min at 94
 

 
C,
(b) 30 cycles of 30 s at 94
 

 
C, 30 s at 57
 

 
C, and 4 min at 72
 

 
C,
and (c) 10 min at 72
 

 
C. A second nested PCR amplification,
which allows amplification of a 357-basepair LTR fragment, was
performed by using 1 
 

 
l of the first reaction with internal HIV-1
LTR primers NI-2 5
 

 
 and NI-2 3
 

 
 (46). This second PCR was
performed using the same PCR conditions as for the first one,
except that the annealing temperature was raised to 60
 

 
C, the ex-
tension time was 1 min, and amplification was run for 25 cycles.
PCR products were analyzed by ethidium bromide/agarose gel
electrophoresis.
 
Immunofluorescence Microscopy.
 
Staining for intracellular p24
CA was performed on YU-2–infected rat microglia from hCD4/
hCCR5-transgenic or hCD4-transgenic rats. Cells were washed
with staining buffer (PBS containing 2% FBS) and then fixed in a
2% paraformaldehyde solution for 1 h on ice. After washing in
staining buffer cells were permeabilized in 0.1% saponin for 15
min at room temperature. Cells were again washed in staining
buffer and then incubated with a FITC-conjugated anti-p24 mAb
(KC57, 1:10; Coulter Immunology) or a FITC-conjugated iso-
type control mAb. Subsequently, cells were stained with the Al-
exa Fluor
 
®
 
 488 Signal-Amplification kit (catalog no. A-11053;
Molecular Probes) following the manufacturer’s instructions. Im-
ages were acquired on an inverted Nikon TE-300 light micro-
scope with SPOT RT digital camera using equal exposure times
and identical digital filtering for all micrographs.
Results
 
Construction of Rats Transgenic for Human CD4 or Human
CCR5.
 
We developed several independent rat lines
transgenic for either hCD4 or hCCR5. In humans, CD4
 

 
T lymphocytes, macrophages, and microglia constitute the
Figure 1. Transgenic rat lines
expressing varying levels of hCD4
or hCCR5. Heparinized blood
taken from (A) hCD4-transgenic
rats, (C) hCCR5-transgenic rats,
or nontransgenic littermate con-
trols were stained with anti-hCD4
or anti-hCCR5 antibodies, re-
spectively, and analyzed by flow
cytometry. (B) Schematic repre-
sentation of the transgenic vector
for hCCR5 (pME4A.CCR5;
for details see Materials and
Methods). E4/P4: murine CD4
enhancer/promoter.
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major reservoirs for HIV-1 replication. To mimic this pat-
tern of susceptible tissues as closely as possible, we sought
to target expression of the HIV-1 receptor complex to
these specific cell types in transgenic rats. For expression of
hCD4, we employed a construct, previously studied in
transgenic mice (12, 32, 48), that contained the murine
 
CD4
 
 enhancer linked to a 30-kb human 
 
CD4
 
 minigene
that included the promoter and all of the exons (32). For
expression of hCCR5, we used a chimeric mouse/human
construct that directs expression of cDNA inserts in cells
from the monocyte/macrophage lineage and Th cells (Fig.
1 B). Because human, but not murine, CD4 is expressed in
the monocyte lineage, this construct was generated with
the murine 
 
CD4
 
 enhancer and promoter plus a human
 
CD4
 
 intron 1 sequence that we found to be required for
expression in monocyte lineage cells, including macro-
phages, dendritic cells, and microglia (unpublished data).
The human intronic sequence also contains the transcrip-
tional silencer that restricts expression to CD4
 

 
 T cells (33).
Rat founders for individual transgenic constructs were
generated by microinjection of the vector DNA into male
pronuclei of fertilized oocytes from outbred Sprague-Daw-
ley rats. Five hCD4 integration founders and three hCCR5
integration founders were identified by Southern blot anal-
ysis or PCR analysis of tail DNA samples, respectively (data
not shown).
As a first assessment of the expression of human trans-
genes in single-transgenic rats, peripheral blood lympho-
cytes from transgene-positive F1 progeny were stained
with fluorochrome-conjugated antibodies specific for ei-
ther hCD4 or hCCR5 and analyzed by flow cytometry.
Three out of five hCD4 founder lines and all three hCCR5
founder lines expressed detectable levels of the respective
human proteins on a subset of peripheral lymphocytes (Fig.
1 A and C). Each transgenic rat line had a unique expres-
sion level ranging from significant to very high, and these
levels have proven to be stable and heritable. Several re-
ports have demonstrated that surface levels of hCD4 or
hCCR5 can be rate-limiting for HIV-1 entry into various
cell types (49, 50). Consequently, in this study the trans-
genic lines with the highest expression levels of human
transgenes, namely hCD4 founder line 3 (Fig. 1 A) and
hCCR5 founder line C (Fig. 1 C), were interbred and used
in subsequent experiments. Transgenic rats coexpressing
hCD4 and hCCR5 were healthy and did not reveal any
gross pathology compared with nontransgenic littermate
controls in analyses of cellular blood composition and a
head-to-tail necropsy (data not shown).
To characterize in more detail the cellular expression
profiles of human transgenes in hCD4/hCCR5-transgenic
rats, we first performed flow cytometry analyses with co-
staining for human transgenic proteins in conjunction with
rat lineage– or lineage subset–specific markers. On periph-
eral lymphocytes from blood (Fig. 2 A, top panels) or
spleen (data not shown), hCD4 and hCCR5 were coex-
pressed on the rat (r)CD4
 

 
 subset, but not expressed on
rCD8
 

 
 T cells or B cells (data not shown). In thymocytes
from transgenic rats both human transgenes were expressed
on rCD4
 

 
 T cells (Fig. 2 A, bottom panels); both the
rCD4
 

 
 rCD8
 

 
 subset, which constitutes the large majority
of thymocytes, and the rCD4
 

 
 rCD8
 

 
 subset, expressed
the transgenes (data not shown). Double-negative thy-
mocytes (rCD4
 
–
 
 rCD8
 
–
 
 cells) had no detectable expression
of either human transgene (data not shown). Expression
analyses were also performed with cells from the mono-
cyte/macrophage lineage isolated from these animals (Fig.
2 B). Since autofluorescence is much higher for these cells
compared with lymphocytes, we used dot plots and two-
parameter analyses in which unstained cells lie on the diag-
onal and positively stained cells are apparent due to their
shift off the diagonal to the right. Using this approach, we
found that macrophages isolated from nontransgenic con-
trol rats showed specific staining for the rat macrophage
marker rED2, but not for hCD4 or hCCR5 (Fig. 2 B, top
row). Importantly, macrophages from hCD4/hCCR5-
transgenic rats expressed hCD4 and hCCR5 on the cell
surface (Fig. 2 B, bottom row). Similarly, hCD4 and
hCCR5 expression was detected on rCD11b/c
 

 
 rCD45
 
low
 
rat microglia (51) cultured ex vivo (data not shown).
Figure 2. Cell type–restricted expression of hCD4 and hCCR5 in
hCD4/hCCR5 transgenic rats. (A) Heparinized blood and thymocytes
from a hCD4/hCCR5 transgenic rat were analyzed by flow cytometry
for the expression of human transgenes and rCD4. Dot plots shown were
gated on the total live lymphocyte population. (B) Subcultured primary
rat spleen macrophages were stained for the expression of hCD4,
hCCR5, or the rat macrophage activation marker rED2. Nontransgenic
rat macrophages served as a control.
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Next, immunohistochemical stainings were performed as
a complementary approach to assessing the expression of
human transgenes, in particular providing insight into the
tissue-specific distribution in situ. In transgenic rats, cells
with the characteristic morphology and distribution pat-
terns of T lymphocytes and macrophages expressed hCD4.
Widespread, intense, and specific cellular hCD4 staining
was detected in lymphocyte-rich spleen and thymus sec-
tions from a hCD4/hCCR5-transgenic rat (Fig. 3 A). Es-
sentially no staining was detectable in tissues from a non-
transgenic control rat with the anti-hCD4 staining (Fig. 3
A), nor did an isotype-matched negative control antibody
yield a signal (data not shown). These results validate our
immunohistochemistry methodology and confirm the re-
sults obtained by flow cytometry. We also conducted the
same analyses with a number of other tissues from these an-
imals. In brain sections, throughout the parenchyma we
detected positive immunostaining in cells of microglial
morphology with highly branched processes (Fig. 3 A).
Similarly, larger cells with macrophage-like morphology
and granular cytoplasm were frequently found in perivas-
cular zones in the brain, most likely representing perivascu-
Figure 3. Selective expression
of hCD4 and hCCR5 in various
tissues from hCD4/hCCR5
transgenic rats. (A–C) Tissues
were removed from saline-per-
fused rats and formalin fixed.
Paraffin-embedded sections were
stained with either (A and B) an
anti-hCD4 antibody or (C) an
anti-hCCR5 antibody and sec-
ondary step reagents. Equal ex-
posure times were used for
comparable micrographs from
transgenic and nontransgenic
sections. Original magnifications
ranged from 40–400	.
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lar macrophages (Fig. 3 B). Expression of the hCD4 trans-
gene was also found in tissue-resident macrophages in all
other tissues analyzed including kidney, liver, and lung
(Fig. 3 B). In the gut, submucosal lymphoid aggregates also
showed abundant staining for hCD4. To define the expres-
sion pattern of hCCR5 in situ, parallel tissue sections from
the same rats were stained with an antibody to this human
chemokine receptor. Abundant expression of hCCR5 was
found exclusively in the transgenic animal (Fig. 3 C); the
expression pattern closely resembled that seen for hCD4,
which was expected since both transgenic constructs share
key regulatory elements. Collectively, these flow cytome-
try and immunohistochemistry data indicate that the ex-
pression of both human cell surface receptors had been
successfully and exclusively targeted to the desired, biologi-
cally relevant cell types, that is, CD4
 

 
 T cells, macro-
phages, and microglia in transgenic rats.
 
Rat Lymphocytes Expressing Human CCR5 Chemotax in
Response to Human 
 


 
–Chemokines.
 
As a first assessment of
the functional integrity of hCCR5 expressed on primary
rat cells, rCD4
 

 
 T lymphocytes from transgenic rats were
tested for in vitro migration toward active human
chemokines at varying concentrations. Lymphocytes from
transgenic rats expressing hCD4 and hCCR5, but not
hCD4 alone, chemotaxed in response to the natural
hCCR5 
 


 
–chemokine ligands human regulated upon acti-
vation, normal T cell expressed and secreted (RANTES)
and human macrophage inflammatory protein (MIP)-1
 

 
(Fig. 4). Similar results were obtained with hMIP-1
 


 
 (data
not shown). The chemotaxis of hCCR5-expressing lym-
phocytes followed a typical biphasic response to increasing
concentrations of human 
 


 
–chemokines (Fig. 4 A). Simi-
lar results were obtained with lymphocytes expressing
hCCR5 in the absence of hCD4 (data not shown). Com-
parable chemotaxis of lymphocyte preparations from trans-
genic and nontransgenic rats toward the CXCR4 ligand
stromal cell–derived factor 1 confirmed cellular viability
and the validity of the assay. These results demonstrate that
hCCR5 in primary transgenic rat cells retained chemo-
kine-mediated signaling functions linked to the proper bi-
ologic responses, suggesting appropriate expression, post-
translational modification, and subcellular localization of
this human seven transmembrane G-protein–coupled re-
ceptor in this species context.
 
Primary Macrophages and Microglia from Transgenic Rats Can
Be Productively Infected by Recombinant and Primary Strains of
HIV-1.
 
To assess whether expression of the HIV-1 re-
ceptor complex on primary rat cells rendered them permis-
sive for viral infection, transgenic macrophages were first
challenged with a set of HIV-1 luciferase reporter viruses.
These pseudotypes are based on an Env-deficient HIV-1
proviral backbone containing the firefly luciferase gene
within the nef gene locus (pNL4–3 Luc E
 

 
R
 

 
; reference
42), expression of which provides a quantitative marker of
successful entry, reverse transcription, integration, and early
viral gene expression in a given target cell. Primary mac-
rophages from double-transgenic rats showed coreceptor-
specific entry and high-level, early HIV-1 gene expression
in ex vivo cultures (Fig. 5 A). Macrophages from hCD4/
hCCR5-transgenic rats were highly permissive for infec-
tion by the R5 Env pseudotypes JR-FL and Ada-M, but
nonpermissive for the hCXCR4-using (X4) Env pseudo-
type NL4–3. As expected, all macrophage cultures were
permissive for the VSV-G pseudotype, which confers entry
into a wide range of mammalian cells. As an additional
control of specificity, pretreatment of hCD4/hCCR5-
expressing rat macrophages with an anti-hCCR5 antibody
reduced signals for the HIV-1 JR-FL Env pseudotype by
94%, but did not significantly affect the infection by the
VSV-G pseudotype (data not shown). The low-level sus-
ceptibility of hCD4 single-transgenic rat macrophages for
R5 pseudotypes may indicate the utilization of an endoge-
nous rat cell surface molecule as an inefficient coreceptor
for HIV-1 entry.
Next, transgenic rat macrophages were challenged with
different, replication-competent strains of HIV-1. Primary
macrophages from hCD4/hCCR5-transgenic rats could be
productively infected by R5 viruses (Fig. 5 B–D). In par-
ticular, double-transgenic rat macrophages challenged with
the recombinant R5 strain YU-2b (37) showed increasing
p24 CA concentrations over the course of 10 d and reach-
ing up to 18 ng per ml (Fig. 5 B). In contrast, rat macro-
Figure 4. 
-chemokine–mediated chemotaxis of
hCCR5-expressing, primary rat T lymphocytes. Single
cell suspensions of spleen from (A) a hCD4/hCCR5-
transgenic rat, and (B) a hCD4-transgenic rat, were en-
riched for rCD4 cells by antibody-mediated depletion
of rCD11b, rCD45R, and rCD8 mononuclear
cells. Subsequently, a transwell chemotaxis assay was
performed using human 
-chemokines hRANTES
and hMIP-1 as specific ligands. human stromal cell–
derived factor 1 served as a positive control for viabil-
ity. The relative number of migrated cells per well
was determined and is presented as the arithmetic
mean  SD of triplicates. Results are representative of
two independent experiments.
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phages single-transgenic for either hCD4 or hCCR5 were
not productively infected, as revealed by p24 CA concen-
trations at background level. The parallel infection of hu-
man monocyte-derived macrophages yielded 9–15-fold
higher p24 CA levels. Importantly, double-transgenic rat
macrophages could be productively infected by a variety of
R5 viruses, including JR-CSF (Fig. 5 C), cloned from the
cerebrospinal fluid of an AIDS patient (52), the primary,
patient-derived isolates C1 (40) (Fig. 5 D) and O3 (41)
(data not shown), as well as the laboratory-adapted, mac-
rophage-tropic strain Ada-M (53) and the NL4–3-based
molecular clone 49.5 carrying the V3 loop from Ba-L (38)
(data not shown).
Next, to investigate further whether these infections
were productive, we studied the effect of a reverse tran-
scriptase or protease inhibitor on HIV-1 infection in mac-
rophages from hCD4/hCCR5-transgenic rats. The reverse
transcriptase inhibitor AZT completely abrogated infection
by YU-2 (Fig. 6 A), demonstrating that the p24 CA signals
depend upon completion of this essential early enzymatic
reaction in the viral life cycle and cannot be accounted for
by input virus. The processing of the HIV-1 polyproteins
p55 Gag and p160 Gag-Pol by the virally encoded protease
into functional subunits is an essential step for HIV-1 mat-
uration. Treatment with a protease inhibitor renders newly
synthesized virus particles noninfectious (54). In cultures
of hCD4/hCCR5-transgenic macrophages infected with
YU-2, the presence of the protease inhibitor RTV signifi-
cantly reduced the secreted p24 CA concentration com-
pared with untreated controls (Fig. 6 A). Based on these
considerations, the infection in double-transgenic mac-
rophage cultures likely represents a spreading infection:
First, transfer of cell-free supernatant from an infected pri-
mary hCD4/hCCR5-transgenic macrophage culture at 5 d
after infection onto a second culture from the same rat led
to a productive infection in the recipient culture (Fig. 6 C),
albeit at low levels. Second, infection of hCD4/hCCR5-
transgenic macrophage cultures with YU-2 at a very “low”
MOI (0.05) resulted in comparable p24 peak concentra-
tions to that achieved in a “high” MOI (0.5) infection, but
with a delay of 
 

 
8 d for the cultures infected at the “low”
MOI (data not shown).
In addition, certain bacterial compounds, including en-
dotoxins like LPS, have under certain conditions been
shown to enhance HIV-1 replication in human cells and
macrophages from HIV-1 provirus-transgenic mice ex vivo
(55, 56). In hCD4/hCCR5-expressing rat macrophages,
both LPS and a formalin-fixed 
 
Staphylococcus aureus
 
 cell sus-
pension measurably enhanced HIV-1 replication (Fig. 6 B).
Collectively, our data indicate that a variety of HIV-1 iso-
lates can efficiently and productively infect primary mac-
rophages from hCD4/hCCR5-transgenic rats in a core-
ceptor-dependent fashion. Furthermore, antiviral drugs
that target specific steps in the viral life cycle inhibit HIV-1
replication in primary ex vivo cultures from transgenic rats.
After these provocative results with macrophages, we
also investigated the permissivity of brain-derived microglia
from transgenic rats. Primary microglia were isolated from
neonatal rat brains, enriched by subcultivation, and charac-
terized as described previously (19). Microglial cultures re-
vealed expected morphologic characteristics, including ruf-
fled edges with occasional long, branched processes, small
and heterochromatic nuclei, granular vesicles within the
cytoplasm, as well as an absence of staining for the astro-
cyte-specific glial fibrillary acidic protein marker (data not
shown). First, to assess the integrity of the early phase of the
Figure 5. Primary rat macrophages coexpressing
hCD4 and hCCR5 are productively infected by re-
combinant and primary strains of HIV-1. (A) Thy-
mus-derived rat macrophages from a hCD4/hCCR5
transgenic rat, a hCD4 transgenic rat, or CD14 hu-
man monocyte–derived macrophages were cul-
tured in 24-well plates and infected with the indi-
cated HIV-1 luciferase reporter pseudotypes. The
luciferase activity in cellular lysates was determined
4 d after infection and is presented here as “relative
light units” per milligrams of protein. (B–D)
Spleen-derived macrophages from hCD4/hCCR5
transgenic rats or single-transgenic rats (hCD4 or
hCCR5 single-positive, as indicated), or human
monocyte–derived macrophages, were infected
with stocks of replication-competent HIV-1
YU-2b, JR-CSF, or the primary isolate C1 (20
ng p24 CA per well) and p24 CA levels in the su-
pernatant were measured at the indicated time
points. All values shown represent arithmetic means
of triplicates  SD.
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HIV-1 replication cycle, microglia were challenged with a
series of HIV-1 luciferase reporter viruses. As seen with
macrophages from hCD4/hCCR5-transgenic rats, double-
transgenic microglia also supported coreceptor-specific en-
try and robust early HIV-1 gene expression (Fig. 7 A).
Comparable results were obtained also for the luciferase re-
porter pseudotype containing the Env from YU-2 or JR-
CSF (data not shown). In contrast, microglia from a non-
transgenic control rat were not permissive for either the R5
or X4 pseudotypes, but were readily infected by the VSV-G
pseudotype. Second, we sought to determine whether
transgenic expression of human entry cofactors on rat
microglia would also confer permissivity for the full
HIV-1 replication cycle. Microglial cultures from a hCD4/
hCCR5-transgenic and a hCD4-transgenic rat were chal-
lenged overnight with the R5 virus YU-2 or VSV-G
pseudotyped NL4–3 (NL4–3/(VSV-G)). The following
day, cultures were extensively washed and 6 d after infec-
tion the p24 CA concentration in culture supernatants was
determined. In addition, microglia were subsequently fixed
and processed for intracellular p24 CA staining. Microglial
cultures from double-transgenic rats, but not nontransgenic
rats, showed clear evidence for productive infection as in-
dicated both by significant levels of secreted p24 CA (Fig. 7
B) and by the abundant presence of intracellular viral capsid
antigen (Fig. 7 C). Interestingly, we occasionally observed
large, syncytia-like, multinucleated cellular aggregates in
these infected cultures, but not in uninfected controls (data
not shown). In contrast, microglia from hCD4 single-trans-
genic control rats secreted significant p24 CA concentra-
tions after infection with NL4–3/(VSV-G), but not after
challenge with the R5 virus (Fig. 7 B). These results dem-
onstrate that coexpression of hCD4 and hCCR5 on micro-
glia from transgenic rats confers coreceptor-specific and
substantial infection by R5 strains of HIV-1.
 
Coexpression of Human CD4 and Human CCR5 Trans-
genes Overcomes the Entry Block in Primary Rat Lymphocytes,
but Does Not Render Them Permissive for Productive HIV-1 In-
fection.
 
We next sought to determine if coexpression of
human transgenes on lymphocytes was also sufficient to
overcome the entry block to HIV-1 infection. Mitogen/
IL-2–activated primary lymphocytes from hCD4/hCCR5-
transgenic rats showed robust signals after infections with
the R5 Env pseudotypes Ba-L, Ada-M, or JR-FL (Fig. 8
A). Luciferase levels in transgenic rat lymphocytes were
only three to sevenfold lower than those seen in parallel in-
fections of activated primary human T lymphocytes. As a
control of specificity, double-transgenic rat lymphocytes
were demonstrated to be nonpermissive to infection by the
X4 Env pseudotype NL4–3, and nontransgenic control
lymphocytes were nonpermissive for either the R5 Env or
the X4 Env pseudotypes. These results demonstrate that
expression of the HIV-1 receptor complex was sufficient to
confer coreceptor-specific entry and robust early, Rev-
independent HIV-1 gene expression in primary CD4
 

 
 T
lymphocytes from transgenic rats.
Challenging the same set of lymphocyte cultures with
the replication-competent R5 virus YU-2b revealed that
hCD4/hCCR5-transgenic lymphocytes did not secrete
significant concentrations of p24 CA (Fig. 8 B), despite
clear signs of progression through the first part of the repli-
cation cycle, including the abundant expression of a Nef/
luciferase reporter (Fig. 8 A). This nonpermissive pheno-
type was also not overcome by other means of activating
rat T lymphocytes, including rCD3/rCD28 costimulation
(data not shown). Similar results were obtained with infec-
tions by the R5 virus Ba-L (data not shown). In contrast,
Figure 6. Effect of antiretroviral drugs and bacterial components on
HIV-1 replication in transgenic rat macrophages. Spleen-derived mac-
rophage cultures from hCD4/hCCR5 transgenic rats were pretreated
with (A) AZT overnight, or RTV, (B) LPS or Staphylococcus aureus extract
for 5 min before challenge with YU-2 (MOI 0.3). Cells were extensively
washed the next day and then continuously cultivated for 10 d in the
presence of the respective reagents. (C) Transfer of cell-free supernatants
from YU-2-infected macrophages from a hCD4/hCCR5 transgenic rat 5 d
after infection onto uninfected cultures from the same rat (p24 CA trans-
ferred: 420 pg [untreated], 1160 pg [LPS]). After overnight infection and
subsequent washing, the supernatant of secondary cultures was monitored
serially for p24 CA concentrations. All p24 CA values shown are the
arithmetic means of triplicates  SD.
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human lymphocytes showed a typical infection kinetic
over the course of 10 d. Thus, cells from the monocyte-
macrophage lineage, but not lymphocytes, from double-
transgenic rats could be productively infected by R5 strains
of HIV-1.
 
Transgenic Rats Can Be Infected With HIV-1 In Vivo.
 
Finally, we sought to address whether transgenic rats could
be infected with HIV-1 in vivo. In a first experiment,
hCD4/hCCR5-transgenic and nontransgenic control rats
(
 
n
 
 
 

 
 4 per group) were challenged intravenously with YU-2.
At day 3 or 16 after the systemic challenge two rats from
each group were killed, and spleens were removed and an-
alyzed for signs of HIV-1 infection. We used a recently de-
scribed PCR approach to detect circularized HIV-1 cDNA
genomes containing two long-terminal repeats (2-LTR
circles) (45). 2-LTR circles are formed from linear full-
length cDNAs that do not integrate into the host genome,
but circularize to form episomes. Their presence in a cell is
an established surrogate for successful cellular entry, reverse
transcription, and nuclear import of HIV-1. Advantages of
this analysis include its unambiguous discrimination from
the genomic RNA of the viral inoculum and its quantita-
tive nature. In all transgenic rats, 2-LTR circles were
readily detectable in splenocyte samples (Fig. 9), both on
day 3 (rat no. 1: 1128 copies per 10
 
8
 
 splenocytes; rat no. 2:
456 copies per 10
 
8
 
 splenocytes) and day 16 (rat no. 3: 608
copies per 10
 
8
 
 splenocytes; rat no. 4: 144 copies per 10
 
8
 
splenocytes) after challenge. In contrast, in none of the
splenocyte samples from the four nontransgenic rats could
2-LTR circle signals be amplified.
In a second in vivo experiment, we sought to detect
proviral DNA that had integrated into the genome of rat
cells following systemic viral challenge. Based on a previ-
ously reported nested PCR strategy to specifically amplify
HIV-1 integrated close to genomic human Alu repeat ele-
ments (46) we developed a similar PCR assay using a
Figure 7. Primary microglia from
hCD4/hCCR5 transgenic rats are
permissive for productive infection
by R5 viruses. (A) Primary microglia
from hCD4/hCCR5 transgenic rats
or nontransgenic control rats cultured
in 96-well plates were challenged
with the indicated pseudotyped
HIV-1 luciferase reporter viruses and
luciferase activity in cellular lysates
was determined 2 d after infection.
Human 293 hCD4/hCCR5 and
HeLa hCD4 cells served as controls.
(B) Microglial cultures from hCD4/
hCCR5 transgenic or hCD4 trans-
genic control rats were infected with
replication-competent YU-2 (1.5 ng
p24 CA per well) or VSV-G pseudo-
typed NL4–3 (NL4–3/[VSV-G]) (0.7
ng p24 CA per well) overnight and
washed extensively the next day,
with a postwash p24 CA concentra-
tion of 300 pg/ml for all cultures.
6 d after infection the p24 CA con-
centration in supernatants was quan-
tified and is represented as arithmetic
means  SEM of triplicates. (C) In-
fected microglia from (B) were
fixed, permeabilized, and processed
for intracellular p24 CA immunocy-
tochemistry. Phase contrasts are
shown on the left, and staining for
p24 CA is shown on the right.
Staining with an isotype control an-
tibody yielded negligible back-
ground signals (data not shown).
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primer specific for a rodent ID family consensus sequence,
that is highly redundant in the rat genome (47) (see Mate-
rials and Methods for details). Integrated proviral DNA
was amplified from genomic DNA samples derived from
spleen samples of a hCD4/hCCR5-transgenic rat (Tg #X)
infected with YU-2 in vivo (Fig. 9 B, lane 7) or from ex
vivo–infected thymocytes as a control (data not shown).
The specific 357 bp product was not amplified from unin-
fected splenocyte samples, splenocyte samples from an in-
fected nontransgenic rat, or thymus samples from Tg #X
(Fig. 9 B, lanes 2–6). Similarly, omission of the ID repeat
primer from the first PCR for DNA samples from spleen
of Tg #X resulted in a loss of the specific product follow-
ing the second PCR (Fig. 9 B, compare lanes 6 and 7),
demonstrating that the exponential amplification of inte-
grated HIV-1 cDNA in the first PCR reaction was neces-
sary for the generation of the LTR-specific product and
that extrachromosomal viral DNA cannot account for the
band observed.
In a third experiment, we sought to visualize and quan-
tify HIV-1 gene expression in vivo directly. Rats were
challenged intravenously with the recombinant R5 virus
R7/3-YU-2-EGFP (39) which carries an EGFP gene
within the 
 
nef
 
 locus driven by the 5
 

 
 LTR. Lymphocytes
and macrophages from spleen (Fig. 10) and PBMCs (data
not shown) from both hCD4/hCCR5-transgenic rats, but
Figure 8. Coexpression of hCD4 and hCCR5 transgenes renders primary rat T lymphocytes permissive for entry and early gene expression of R5 vi-
ruses, but does not allow for a productive infection. (A) Mitogen/IL-2–activated, spleen-derived lymphocytes from a hCD4/hCCR5-transgenic rat, a
nontransgenic littermate control rat or human lymphocytes were infected with the indicated pseudotyped HIV-1 luciferase reporter viruses. Luciferase
activity in cellular lysates was determined 4 d after infection. (B) In parallel, the same lymphocyte cultures were infected with the replication-competent
R5 strain YU-2b. The HIV-1 p24 CA concentration in culture supernatants was determined at the indicated time points. All values represent the arith-
metic means  SD of triplicates.
Figure 9. Detection of episomal and integrated HIV-1
cDNA in splenocytes from transgenic, but not nontrans-
genic rats, challenged with HIV-1 in vivo. (A) hCD4/
hCCR5 transgenic and nontransgenic control rats (n  4
per group) were challenged with YU-2 (8 	 105 TCID50
per rat), intravenously. On either day 3 or 16 after challenge
two rats from each group were killed and spleens removed.
Nuclear extrachromosomal DNA was isolated from sple-
nocytes and analyzed for the presence of 2-LTR circles by
PCR as described recently (reference 45). Shown is an
ethidium bromide-stained gel of PCR products. Positive
control: Ex vivo–infected hCD4/hCCR5 transgenic sple-
nocytes; negative control: no DNA. (B) A hCD4/
hCCR5-transgenic (Tg #X) and a nontransgenic rat
(NTg) were infected with YU-2 (5 	 107 TCID50 per rat)
intravenously and spleen and thymus were harvested on
day 5 after challenge. Integrated proviral DNA in genomic
extracts was detected by nested PCR (see Materials and
Methods for details). Lanes: (1) no template; (2) NTg
spleen; (3) Uninfected Tg #Y spleen; (4) Tg #X thymus,
no ID primer; (5) Tg #X thymus; (6) Tg #X spleen, no
ID primer; (7) Tg #X spleen. Except for lanes 4 and 6
both ID primer BC1-A and LTR primer A were added to
the first PCR reaction. Shown is an ethidium bromide-
stained gel of the expected 357 bp PCR product.
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not from the infected nontransgenic rats or an uninfected
transgenic rat, contained a significant population of GFP
 

 
cells (Fig. 10, and data not shown). A further indication of
specificity was that the overwhelming majority of GFP
 

 
cells were rCD4
 

 
 cells (Fig. 10 A), which are the only cells
that in these animals express the HIV-1 receptor complex.
The frequency of GFP
 

 
rCD4
 

 
 splenocytes was 
 

 
0.15%
for lymphocytes and 2% for macrophages in transgenic
rats (Fig. 10 B). In peripheral blood the frequency of
GFP
 

 
rCD4
 

 
 lymphocytes was 
 

 
0.01%, with a 10-fold
lower background frequency in nontransgenic rats (data
not shown).
In a fourth experiment, hCD4/hCCR5-transgenic and
nontransgenic control rats (
 
n
 
 
 

 
 6 per group) were chal-
lenged with YU-2 by intraperitoneal inoculation. Also, a
group of mock-infected double-transgenic control rats was
included in this study. Control rats exhibited no gross clin-
ical abnormalities through the postinoculation observation
period. Unexpectedly, one HIV-1-inoculated transgenic
rat (#521) was observed to have a generalized tonic-clonic
seizure 21 d after infection, from which it recovered spon-
taneously. This transgenic animal was found dead at 43 d
after infection, but pathologic assessment was obscured by
severe postmortem tissue degradation during the time in-
terval from death to discovery.
Plasma viral loads were monitored in all of these rats
weekly for 7 wk after inoculation, and again at three sub-
sequent time points (weeks 11, 13, and 25 after inocula-
tion) (Fig. 11). All samples from the nontransgenic con-
trol animals and mock-infected double-transgenic rats
(data not shown) were negative (
 

 
20 HIV-1 RNA copies
per milliliter), indicating the specificity of the experimen-
tal system. In contrast, at least one plasma sample each
from five of six inoculated hCD4/hCCR5-transgenic rats
was positive (range: 20–151 HIV-1 RNA copies per mil-
liliter), while three of them had positive samples at two
separate time points. The latest time point for which
plasma viremia was detected was 7 wk after inoculation
Figure 10. Early HIV-1 gene expression in splenocytes
from hCD4/hCCR5 transgenic rats after intravenous in-
fection with R7/3-YU-2-EGFP. Nontransgenic (rat A and
B) and double-transgenic rats (rat C and D) were challenged
with R7/3-YU-2-EGFP (9 	 106 TCID50 per rat). On day
4 after infection, spleen and PBMC samples were har-
vested and analyzed by multicolor FACS® analysis. (A)
Splenocytes were gated on “lymphocyte” and “macrophage”
populations based on FSC/SSC profiles previously defined
by backgating of rCD3 and rCD11b/c  cells, respec-
tively (data not shown). Viable, 7-AAD cells in the re-
spective gates are presented as dot plots showing GFP
expression relative to rCD4(APC) expression. (B) Quanti-
tative analysis of GFP rCD4 splenocyte subsets. Data on
4 	 106 cells were acquired for each sample.
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(#599). At 6 mo after inoculation, two rats from each
group were killed (hCD4/hCCR5-transgenic, HIV-1-
infected: #513, #532; nontransgenic, HIV-1 infected:
#530, #568; hCD4/hCCR5-transgenic, mock-infected:
#584, #615) and spleen and thymus samples were ana-
lyzed for the presence of 2-LTR circles. Only the tissues
from HIV-1 infected, transgenic rats (#513 (spleen) and
#532 (spleen and thymus) contained low, but detectable
numbers of 2-LTR circles, ranging from 36–108 copies
per organ.
Discussion
The development of a transgenic small animal model
permissive for HIV-1 infection would aid the study of viral
transmission, pathogenesis, and the testing of therapeutic
strategies including vaccines. A major obstacle to this end
has been the inability of cells from present transgenic rabbit
or mouse models to support a robust productive HIV-1 in-
fection (11, 12, 57). We have previously shown that cellu-
lar entry constitutes the only absolute block to HIV-1 rep-
lication in certain rat cell lines, and that this restriction can
be overcome by coexpression of hCD4 and hCCR5 (19).
Studies with pseudotyped HIV-1 revealed that primary
cells from the monocyte/macrophage lineage from various
rat strains supported all steps in the viral replication cycle,
including the production of infectious HIV-1. Based on
these findings, we hypothesized that reconstitution of the
HIV-1 receptor complex in rats would overcome the entry
block in primary cells and recapitulate the full viral replica-
tion cycle in at least some cell types such as macrophages.
Specifically, the mouse CD4 enhancer and the human
CD4 intron 1, which contains a monocyte lineage-specific
enhancer (unpublished data), were included in both trans-
genes, as was the human intronic silencer that shuts off
CD4 expression in CD8 lineage T cells. A definitive mu-
rine promoter element for CCR5 has not yet been identi-
fied, and this strategy assured coexpression of hCD4 and
hCCR5, which is an absolute requirement for efficient cel-
lular entry of R5 viruses. Several independent, single-trans-
genic rat lines were generated that displayed distinct ex-
pression levels of human transgenes. Detailed expression
analyses using flow cytometry and immunohistochemistry
indicated that both hCD4 and hCCR5 had been success-
fully and exclusively targeted to the desired, biologically
relevant cell types in transgenic rats.
Although hCCR5-mediated signaling is not required for
HIV-1 infection (34, 58, 59), coreceptor-mediated signal-
ing events induced by R5 Env have been suggested to be
contributory to HIV-1–related pathology (60, 61). We
thus sought to determine whether or not hCCR5 ex-
pressed on primary cells from transgenic rats preserved its
competence as a signal-transducing chemokine receptor.
We found that hCCR5-expressing lymphocytes chemo-
taxed in response to the natural human ligands for hCCR5,
the 
-chemokines hRANTES, hMIP-1, and hMIP-1
,
demonstrating that hCCR5 in primary transgenic rat cells
retained signaling functions linked to the proper biologic
responses. In this context it is also noteworthy that trans-
genic rats expressing high levels of hCCR5 were healthy
and did not reveal any gross abnormalities, particularly
within the hematopoietic system. This observation is con-
sistent with the absence of a known physiological pheno-
type in humans that express markedly different levels of
hCCR5 (30).
Coexpression of hCD4 and hCCR5 in transgenic rats
indeed rendered primary rat cells susceptible to entry of
HIV-1. This process was both hCD4-dependent and core-
ceptor-specific as demonstrated by several lines of experi-
mental evidence. First, single-transgenic or nontransgenic
rat cells were largely nonpermissive. Second, double-trans-
genic cells were permissive selectively for R5, but not
X4, viruses. Third, an anti-hCCR5 antibody specifically
blocked infection by an R5 virus. Moreover, entry was not
restricted to specific R5 Env, since diverse R5 strains tested
were capable of infecting hCD4/hCCR5-expressing pri-
mary rat cells. These results suggest that hCD4 and hCCR5
expressed in transgenic rats have the required posttransla-
tional modifications and appropriate subcellular localization
to function as an efficient HIV-1 receptor complex in this
species context.
Consistent with our earlier studies on nontransgenic rat-
derived cells (19), we found that primary cells from the
monocyte/macrophage lineage from hCD4/hCCR5-
transgenic rats allowed for a productive infection by R5 vi-
ruses in ex vivo cultures. Remarkably, levels of productive
infection were one to two orders of magnitude higher than
those described for comparable transgenic mouse models
Figure 11. Plasma viremia in hCD4/hCCR5 transgenic
rats after intraperitoneal inoculation with YU-2. Six dou-
ble-transgenic and six nontransgenic rats were inoculated
intraperitoneally with YU-2 (107 TCID50 per rat). Plasma
sampling was performed at each of the time points identi-
fied with a bold number on the x-axis (weeks 1, 2, 3, 4, 5,
6, 7, 11, 13, and 25 after infection) and HIV-1 vRNA
concentrations were determined by the ultrasensitive
Roche Amplicor HIV-1 Monitor tests with a limit of de-
tection of 20 HIV-1 RNA copies per milliliter. Shown in
this figure are all plasma samples with detectable viremia
(transgenic rats 513, 602, 521, 532, and 599). None of the
samples from the nontransgenic rats (rats 530, 568, 603,
655, 706, and 523) or one of six transgenic rats (rat 518)
scored positive in this analysis.
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(11, 12). R5 primary isolates, molecular clones, and re-
combinant strains of HIV-1 were all capable of produc-
tively infecting hCD4/hCCR5 transgenic rat macro-
phages. Furthermore, the significant inhibitory effect of a
reverse transcriptase and a protease inhibitor further con-
firmed the productive nature of viral replication in these
transgenic rat macrophage cultures. Evidence from low
MOI inoculations and from supernatant transfer experi-
ments suggests that the infection in these ex vivo macro-
phage cultures was spreading. This fact is consistent with
our earlier observation that virus released by primary rat
macrophages is highly infectious (19). These findings are
also important to provide context for the interpretation of
viral dynamics in vivo.
In humans, macrophages and microglia are important
targets of HIV-1 that support virus replication in vivo (62–
66). Several studies have implicated macrophages as a long-
term reservoir for HIV-1 in infected individuals (67, 68)
and macrophages have been suggested as a source of in-
creasing viremia in later stages of HIV disease, particularly
during opportunistic infections (69). Similarly, in a Rhesus
macaque study, macrophages were implicated as the princi-
pal reservoir for sustained high virus load after the deple-
tion of CD4 T cells by a simian immunodeficiency virus
(SIV)/HIV-1 chimera (70). Regarding the pathophysiol-
ogy of acute CNS infection by HIV-1, histological studies
of specimens from HIV-1–infected humans and SIV-
infected rhesus macaques have demonstrated that lympho-
cytes and monocytes migrate into the brain early in infec-
tion (71, 72). A recent study in SIV-infected macaques
indicated that perivascular macrophages, which are fre-
quently replenished by peripheral monocytes/macro-
phages, are the earliest and primary cell type infected in the
CNS (73), but the role of lymphocytes in the development
of HIV-associated dementia is still unclear. One might
speculate that in vivo infections of transgenic rats could
provide some insight into this question since productive in-
fection of monocytes/macrophages and T lymphocytes ap-
peared to be naturally uncoupled in these animals (see be-
low). Also, macrophages and microglia are thought to be
crucial for the development of HIV-associated dementia
because they are the only resident cells that can be produc-
tively infected at high levels in the CNS (for a review, see
reference 74). Thus, based on the ex vivo data from
hCD4/hCCR5 transgenic rats, it is conceivable that certain
aspects of HIV-associated CNS pathology can be recapitu-
lated in this small animal model.
Unlike macrophages, primary T lymphocytes from
hCD4/hCCR5-transgenic rats were found to harbor a
major posttranscriptional block to HIV-1 replication. The
early phase of the viral replication cycle was fully intact,
since infections by different R5 pseudotypes yielded abun-
dant signals from luciferase reporter viruses. We have pre-
viously established that luciferase expression in this cell
context is a useful surrogate for HIV-1 Nef protein ex-
pression (19). Although the expression level of this re-
porter gene in rat T cells was only three to sevenfold
lower than that found in human lymphocytes, infected
transgenic rat lymphocytes failed to secrete significant con-
centrations of p24 CA. The nonproductive infection of rat
lymphocytes was similarly observed previously following
infections by HIV-1/(VSV-G), which also demonstrated
that there was no significant de novo synthesis of Gag
products in rat lymphocytes despite abundant early, Rev-
independent gene expression (19). These findings are con-
sistent with an impaired function of Rev in promoting the
nuclear export of unspliced viral transcripts in this cell
type. This hypothesis is also supported by a recent study
on HIV-1 provirus transgenic rats, which revealed the ab-
sence of unspliced viral transcripts from the majority of tis-
sues analyzed (20). Future investigation will be needed to
define the exact nature of the block in primary rat T cells
affecting the transition from the early to the late phase of
the viral replication cycle. In the context of an NL4–3
provirus-transgenic mouse model, macrophages, but not
lymphocytes, were found to upregulate the expression of
p24 CA and infectious virus after polyclonal stimulation
(56, 75). In contrast, another study on JR-CSF transgenic
mice indicated that comparable, low levels of infectious
virus were being released from primary monocytes, as well
as T and B lymphocytes (76). It is thus unclear whether
mice share this cell type-specific restriction to HIV-1 rep-
lication evident in rats. On one hand, the failure of HIV-1
replication to proceed beyond early gene expression in
primary rat T lymphocytes may help to dissect mecha-
nisms of CD4 T cell depletion in an in vivo model. Spe-
cifically, transgenic rat T cells should provide a tool to
study the individual quantitative and qualitative contribu-
tions of hCCR5-mediated signaling to HIV-1 pathology
(60, 61, 77, 78) and to study the importance of early HIV-1
gene products for T cell pathology, since infection results
in the expression of these products at physiological levels
in the absence of structural HIV-1 gene products. For ex-
ample, the early HIV-1 Nef protein itself has been sug-
gested to harbor a major determinant of pathogenicity for
an AIDS-like disease induced by transgenic expression in
mice (79). On the other hand, the identification of cellular
factors that are essential for HIV-1 replication and that
may surmount restrictions in primary rat T lymphocytes
would both provide a better understanding of the molecu-
lar aspects of HIV-1 replication and increase the range of
applications of a transgenic rat model.
In a first set of studies seeking to establish whether or not
rat cells in vivo are permissive for HIV-1 infection, sys-
temic challenge with R5 viruses yielded definitive evidence
for viral infection in cells from spleen, peripheral blood,
and thymus. Cells from hCD4/hCCR5 transgenic, but not
nontransgenic rats, contained episomal 2-LTR circles as
well as integrated proviral DNA. Early viral gene expres-
sion, represented by an EGFP reporter expressed from the
nef gene locus, was found in rCD4 lymphocytes and mac-
rophages in double-transgenic rats. Interestingly, the fre-
quency of infected CD4 lymphocytes in the spleen of
transgenic rats (0.14–0.18%) was in the same range as those
described in spleen sections from AIDS patients (0.09–
0.64%) in a recent report (80). Our results constitute the
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first demonstration of a quantitative HIV-1 infection of
lymphoid tissues in a transgenic rodent.
It has been suggested that 2-LTR circles are labile, both
in vitro and in vivo, relative to integrated viral genomes,
and thus indicative of a recent cellular infection event (45).
Further investigations will be required to define the nature
of the persistence of 2-LTR circles in transgenic rats, and
specifically whether or not this persistence reflects multiple
rounds of replication. The detectable, albeit low, levels of
2-LTR circles in spleen and thymus samples from trans-
genic rats 6 mo after inoculation are encouraging in this re-
spect. In addition, we found that transgenic rats challenged
with YU-2 intraperitoneally had detectable plasma viremia
up to 7 wk after infection. Although the sample size is small
and the levels of viremia were modest, these findings imply
that a productive infection may occur in this rodent model.
Also, detectable plasma viremia in one transgenic rat
(#521) correlated in time with an observed neurological
event before an unexplained, spontaneous death.
Taken together, our data demonstrate that hCD4/
hCCR5 transgenic rats are promising candidates for a small
animal model of HIV-1 infection. Whether the productive
infection of cells from the monocyte/macrophage lineage
will be sufficient for sustained viral loads in vivo and/or in-
duction of HIV-induced pathogenesis in the present form
of the model is currently under investigation. A recent
study reported that HIV-1 provirus transgenic rats devel-
oped HIV-related pathologies and immunologic dysfunc-
tion (20). This indicates that HIV-1 gene expression in this
species may be sufficient to recapitulate certain aspects of
the disease in humans, and provides an additional basis for
optimism that HIV-related pathology will be found in the
hCD4/hCCR5-transgenic rat model. Such a system for de
novo infection would provide unique experimental oppor-
tunities for elucidating aspects of viral transmission, viral
dynamics, HIV-1 pathogenesis, immune responses, and ef-
ficacy of therapeutic strategies aimed at diverse aspects of
the viral life cycle. A systematic assessment of in vivo infec-
tions in hCD4/hCCR5-transgenic rats will be needed to
define in more detail the features and limitations of this
model system, as well as opportunities for enhancement
based on further genetic and biological manipulation.
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